Looking to publish in Blood Cancer Journal? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Existing customer loginBlood Cancer Journal is a peer-reviewed fully open access journal dedicated to publishing articles related to hematologic malignancies and related disorders.
Looking to publish in Blood Cancer Journal? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Existing customer loginSubmission Instructions
Blood Cancer Journal accepts the following article types. Click on an article type to view submission instructions.
Article
Review Article
Current Treatment Algorithm
Correspondence
Recent Publications
Improving survival and narrowing age disparities in mantle cell lymphoma across therapeutic eras
Malak Munir, John L. Vaughn, Sravani Rimmalapudi, Narendranath Epperla
An all-oral triplet regimen (decitabine/cedazuridine, venetoclax, and gilteritinib) for newly diagnosed and relapsed/refractory FLT3-mutated AML and high-risk MDS
Roberta S. Azevedo, Nicholas J. Short, Alex Bataller, Naval Daver, Tapan M. Kadia, Courtney DiNardo, Alexandre Bazinet, Ghayas Issa, Elias Jabbour, Gautam Borthakur, Jayastu Senapati, Wei-Ying Jen, Kelly Chien, Steven Kornblau, Dono Tippett, Musa Yilmaz, Guillermo Montalban-Bravo, Xuelin Huang, Wei Qiao, Hagop Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi
Glucagon-like peptide-1 receptor agonists and risk for hematologic malignancies: a multicenter propensity score-matched analysis
Pratik Shah, Adit Singhal, Tsu Hsien Wang, Albert Ko, Yu-Cheng Chang, Anita Ng, Andrew Shih, Yuan Ping Hsia, Cho-Hung Chiang, Cho-Han Chiang
Targeting FcRL5 in multiple myeloma: biological rationale and strategic sequencing beyond BCMA and GPRC5D
Xuehang Fu, Mengping Chen, Xiaoli Hu, Junying Wang, Jian Hou, Juan Du
Subcutaneous isatuximab by on-body-injector plus bortezomib, lenalidomide, and dexamethasone in newly diagnosed transplant-ineligible multiple myeloma: ISASOCUT study
Arthur Bobin, Lisa Durocher, Cyrille Touzeau, Nicolas Branche, Aurore Perrot, Mamoun Dib, Jean-Sébastien Blade, Thomas Chalopin, Lydia Montes, Julie Gay, Mourad Tiab, Margaret Macro, Titouan Cazaubiel, Frédérique Orisini Piocelle, Alberto Santagostino, Adrienne De Thomas De Labarthe, Marlène Ochmann, Christophe Roul, Reza Tabrizi, Muriel Newinger-Porte, Olivier Fitoussi, Mony Morisse Chenda, Rick Zhang, Douaa Dhahri, Murielle Roussel, Lionel Karlin, Mohamad Mohty, Philippe Moreau, Anaïs Schavgoulidze, Jill Corre, Thierry Facon, Cyrille Hulin, Salomon Manier, Stéphanie Ragot, Xavier Leleu
Frequently asked questions
How long does it take to publish?
Reviewers are given 14 days from acceptance to submit their reports. Revision requests are used when authors can address concerns in six months or less. Accepted articles are published immediately as an Article in Press. Proof corrections must be returned within 48 hours of receipt.
Reformat to Blood Cancer Journal using Livewrite PremiumIs a cover letter required?
A cover letter is required. It should include the corresponding author's affiliation and contact information, explain the importance of the work and its suitability for the journal's readership, confirm originality and exclusive submission, include previous reviewer comments if the manuscript was considered elsewhere, and include a Competing Interests statement.
Reformat to Blood Cancer Journal using Livewrite PremiumWhat are the publication costs?
An article processing charge is required. Original Research: £3690.00/$5490.00/€4390.00; Letter / Correspondence / Comment: £1215.00/$1675.00/€1515.00, subject to VAT or local taxes where applicable.
Reformat to Blood Cancer Journal using Livewrite Premium